+Follow
F4N33
No personal profile
3
Follow
2
Followers
0
Topic
0
Badge
Posts
Hot
F4N33
2021-06-30
To the moon
Sorry, the original content has been removed
F4N33
2021-06-30
Like
F4N33
2021-06-14
??
Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":3576578208214569,"uuid":"3576578208214569","gmtCreate":1613484184592,"gmtModify":1625065523991,"name":"F4N33","pinyin":"f4n33","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":3,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":151351382,"gmtCreate":1625064783046,"gmtModify":1703735335914,"author":{"id":"3576578208214569","authorId":"3576578208214569","name":"F4N33","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151351382","repostId":"1105779613","repostType":4,"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151327703,"gmtCreate":1625064673402,"gmtModify":1703735330818,"author":{"id":"3576578208214569","authorId":"3576578208214569","name":"F4N33","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like ","listText":"Like ","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151327703","isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184037648,"gmtCreate":1623677740084,"gmtModify":1704208418430,"author":{"id":"3576578208214569","authorId":"3576578208214569","name":"F4N33","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184037648","repostId":"2143609782","repostType":4,"repost":{"id":"2143609782","pubTimestamp":1623669938,"share":"https://www.laohu8.com/m/news/2143609782?lang=&edition=full","pubTime":"2021-06-14 19:25","market":"us","language":"en","title":"Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2143609782","media":"Investing.com","summary":"Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after","content":"<p>Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.</p>\n<p>The trial had 29,960 participants across the U.S. and Mexico.</p>\n<p>The vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.</p>\n<p>Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.</p>\n<p>Once authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.</p>\n<p>Barring J&J’s, all are two-dose vaccines.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 19:25 GMT+8 <a href=https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective....</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143609782","content_text":"Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.\nThe trial had 29,960 participants across the U.S. and Mexico.\nThe vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.\nUpon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.\nOnce authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.\nBarring J&J’s, all are two-dose vaccines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":151351382,"gmtCreate":1625064783046,"gmtModify":1703735335914,"author":{"id":"3576578208214569","authorId":"3576578208214569","name":"F4N33","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151351382","repostId":"1105779613","repostType":4,"repost":{"id":"1105779613","pubTimestamp":1625062867,"share":"https://www.laohu8.com/m/news/1105779613?lang=&edition=full","pubTime":"2021-06-30 22:21","market":"us","language":"en","title":"Tesla Stall Shows Wall Street Rift on Stratospheric Stock Value","url":"https://stock-news.laohu8.com/highlight/detail?id=1105779613","media":"Bloomberg","summary":"One analyst sees it rising to $1,200, another tumbling to $150. Competitive threats build after meteoric 2020 stock surge. Few companies have been as polarizing on Wall Street as Tesla Inc.-- and the lackluster run this year has done nothing to lessen it.To Piper Sandler & Co.’s Alexander Potter, the company’s potential dominance of the electric-car business warrants a $1,200 stock-price target, nearly double its $680.76 close on Tuesday. To Craig Irwin of Roth Capital Partners, as rivals move t","content":"<ul>\n <li>One analyst sees it rising to $1,200, another tumbling to $150</li>\n <li>Competitive threats build after meteoric 2020 stock surge</li>\n</ul>\n<p>Few companies have been as polarizing on Wall Street as Tesla Inc.-- and the lackluster run this year has done nothing to lessen it.</p>\n<p>To Piper Sandler & Co.’s Alexander Potter, the company’s potential dominance of the electric-car business warrants a $1,200 stock-price target, nearly double its $680.76 close on Tuesday. To Craig Irwin of Roth Capital Partners, as rivals move to pick off a head start that turned Tesla into the world’s most highly valued car company, the stock will sink to $150.</p>\n<p>The divergence illustrates the tension that has sent Tesla shares toward a 4% loss during the first half of the year even as rival automakers surged ahead. That’s a marked contrast to its more than 8-fold jump last year and reflects investors’ doubts about heady growth expectations for the company in the face of stronger competitive threats and signs of a sales slowdown in China.</p>\n<p>“For a long time Tesla was the only credible player in the high-quality EV market, and we are seeing that starting to change,” said JoAnne Feeney, portfolio manager atAdvisorsCapital Management, who said the company’s current valuation assumes it will become the biggest seller of cars in the U.S. “That seems to be an awful lot to ask.”</p>\n<p><img src=\"https://static.tigerbbs.com/fb8f7a35e4b2bc516159737958ead3d4\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"></p>\n<p>Tesla sold about half a million cars worldwide in 2020, accounting for a fraction of even the 14.5 million light vehicles sold in the U.S., and it’s facing threats from traditional automakers such as General Motors Co.,Ford Motor Co. and Volkswagen AG that are launching their own electric-vehicle lineups. In China, Tesla’s lead over other startups has already started to shrink, according to UBS Group AG analyst Patrick Hummel.</p>\n<p>That competition poses a separate challenge to the company’s bottom line: Tesla has profited from selling carbon-offset credits to other carmakers that haven’t met their emissions targets. But the more its rivals’ sales of electric vehicles take off, the more that source of revenue will drop.</p>\n<p>Yet Tesla’s stock-market valuation is based on the expectation of steep growth, giving it little room for error. It’s currently trading at more than 650 times earnings per share, according to data compiled by Bloomberg. That compares with a multiple of 30 for the S&P 500 Index.</p>\n<p>“Tesla’s market valuation is vastly over optimistic, ignoring the over 500 EV models that will be on the road by the end of 2025,” said Roth Capital’s Irwin. “Tesla does not operate in a vacuum and many companies have better technology.”</p>\n<p>The company will be reporting second-quarter delivery figures later this week, a major catalyst that analysts and investors will be keenly watching.</p>\n<p><img src=\"https://static.tigerbbs.com/6d2dd8d41a7f20e74bd44de1c344d6a0\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"></p>\n<p>But Tesla bulls are confident that the company’s valuation will be justified if it comes to dominate the industry, much like tech behemoths Alphabet Inc.,FaceBook Inc. and Amazon.com Inc .have come to lord over their’s.</p>\n<p>Others just see it as a pause for Tesla shares as investors come to terms with the surging valuation last year, when markets leaned heavily onto growth stocks as the pandemic shut down much of the global economy. That influx has started to shift this year in the so-called reflation trade, with funds moving back into stocks more likely to benefit from the recovery.</p>\n<p>Cathie Wood’s Ark Investment Management, which had a 0.6% stake in Tesla as of March 31 and is an ardent backer of the company, remains steadfast in its support despite the stock’s showing this year. Ark expects it to benefit from rising electric vehicle sales and sees even odds that it will deliver fully self-driven cars in four years.</p>\n<p>If all goes as planned? Ark forecasts the stock will reach $3,000 in 2025.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stall Shows Wall Street Rift on Stratospheric Stock Value</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stall Shows Wall Street Rift on Stratospheric Stock Value\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 22:21 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-06-30/tesla-stall-shows-wall-street-rift-on-stratospheric-stock-value?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One analyst sees it rising to $1,200, another tumbling to $150\nCompetitive threats build after meteoric 2020 stock surge\n\nFew companies have been as polarizing on Wall Street as Tesla Inc.-- and the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-30/tesla-stall-shows-wall-street-rift-on-stratospheric-stock-value?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-30/tesla-stall-shows-wall-street-rift-on-stratospheric-stock-value?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105779613","content_text":"One analyst sees it rising to $1,200, another tumbling to $150\nCompetitive threats build after meteoric 2020 stock surge\n\nFew companies have been as polarizing on Wall Street as Tesla Inc.-- and the lackluster run this year has done nothing to lessen it.\nTo Piper Sandler & Co.’s Alexander Potter, the company’s potential dominance of the electric-car business warrants a $1,200 stock-price target, nearly double its $680.76 close on Tuesday. To Craig Irwin of Roth Capital Partners, as rivals move to pick off a head start that turned Tesla into the world’s most highly valued car company, the stock will sink to $150.\nThe divergence illustrates the tension that has sent Tesla shares toward a 4% loss during the first half of the year even as rival automakers surged ahead. That’s a marked contrast to its more than 8-fold jump last year and reflects investors’ doubts about heady growth expectations for the company in the face of stronger competitive threats and signs of a sales slowdown in China.\n“For a long time Tesla was the only credible player in the high-quality EV market, and we are seeing that starting to change,” said JoAnne Feeney, portfolio manager atAdvisorsCapital Management, who said the company’s current valuation assumes it will become the biggest seller of cars in the U.S. “That seems to be an awful lot to ask.”\n\nTesla sold about half a million cars worldwide in 2020, accounting for a fraction of even the 14.5 million light vehicles sold in the U.S., and it’s facing threats from traditional automakers such as General Motors Co.,Ford Motor Co. and Volkswagen AG that are launching their own electric-vehicle lineups. In China, Tesla’s lead over other startups has already started to shrink, according to UBS Group AG analyst Patrick Hummel.\nThat competition poses a separate challenge to the company’s bottom line: Tesla has profited from selling carbon-offset credits to other carmakers that haven’t met their emissions targets. But the more its rivals’ sales of electric vehicles take off, the more that source of revenue will drop.\nYet Tesla’s stock-market valuation is based on the expectation of steep growth, giving it little room for error. It’s currently trading at more than 650 times earnings per share, according to data compiled by Bloomberg. That compares with a multiple of 30 for the S&P 500 Index.\n“Tesla’s market valuation is vastly over optimistic, ignoring the over 500 EV models that will be on the road by the end of 2025,” said Roth Capital’s Irwin. “Tesla does not operate in a vacuum and many companies have better technology.”\nThe company will be reporting second-quarter delivery figures later this week, a major catalyst that analysts and investors will be keenly watching.\n\nBut Tesla bulls are confident that the company’s valuation will be justified if it comes to dominate the industry, much like tech behemoths Alphabet Inc.,FaceBook Inc. and Amazon.com Inc .have come to lord over their’s.\nOthers just see it as a pause for Tesla shares as investors come to terms with the surging valuation last year, when markets leaned heavily onto growth stocks as the pandemic shut down much of the global economy. That influx has started to shift this year in the so-called reflation trade, with funds moving back into stocks more likely to benefit from the recovery.\nCathie Wood’s Ark Investment Management, which had a 0.6% stake in Tesla as of March 31 and is an ardent backer of the company, remains steadfast in its support despite the stock’s showing this year. Ark expects it to benefit from rising electric vehicle sales and sees even odds that it will deliver fully self-driven cars in four years.\nIf all goes as planned? Ark forecasts the stock will reach $3,000 in 2025.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184037648,"gmtCreate":1623677740084,"gmtModify":1704208418430,"author":{"id":"3576578208214569","authorId":"3576578208214569","name":"F4N33","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184037648","repostId":"2143609782","repostType":4,"repost":{"id":"2143609782","pubTimestamp":1623669938,"share":"https://www.laohu8.com/m/news/2143609782?lang=&edition=full","pubTime":"2021-06-14 19:25","market":"us","language":"en","title":"Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2143609782","media":"Investing.com","summary":"Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after","content":"<p>Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.</p>\n<p>The trial had 29,960 participants across the U.S. and Mexico.</p>\n<p>The vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.</p>\n<p>Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.</p>\n<p>Once authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.</p>\n<p>Barring J&J’s, all are two-dose vaccines.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 19:25 GMT+8 <a href=https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective....</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143609782","content_text":"Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.\nThe trial had 29,960 participants across the U.S. and Mexico.\nThe vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.\nUpon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.\nOnce authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.\nBarring J&J’s, all are two-dose vaccines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151327703,"gmtCreate":1625064673402,"gmtModify":1703735330818,"author":{"id":"3576578208214569","authorId":"3576578208214569","name":"F4N33","avatar":"https://static.tigerbbs.com/da8514f1475f2fac9413144ad48b12e0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like ","listText":"Like ","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151327703","isVote":1,"tweetType":1,"viewCount":61,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
